Fig. 3:

Circulating cell-free miR-375 in serum discriminates MCC patients with and without presence of disease: The retrospective discovery and training cohorts.

A, B: cf miR-375 in sera of MCC patients was determined by RT-qPCR in duplicate, and normalized to spiked-in cel-mir-39. Values were calculated relative to the serum of a MCC patient with no evidence of disease (Graz cohort) by the 2-ΔΔCq method. Results are depicted in Cleveland dot plots categorized in patients with no (NED) or with evidence of disease. C, D: Receiver operating characteristic (ROC) curves showing the sensitivity and specificity of miR-375 serum levels to discriminate tumor-bearing versus NED patients. The areas under the curve (AUC), optimal cut-off values and their sensitivity and specificity are given. A, C: Graz cohort; B, D: Seattle cohort. Patients’ characteristics are given in S. Tab. 3 and 4. The horizontal line indicates the median, Mann-Whitney U test and pROC R were performed as described in Statistical analysis; p***<0.001